However, a large number of drug studies are still limited to targeting NLRP3 or NLRP1/caspase-1/GSDMD classical pyroptosis pathway to inhibit neuronal pyroptosis in AD-related regions and thus alleviate AD symptoms. This evidence concerns the gene NLRP1 and Alzheimer disease.